Lv3
360 积分 2023-09-12 加入
Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial
1个月前
已完结
LBA4 Phase III study of ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small cell lung cancer (HARMONi-6)
1个月前
已完结
Pharmacokinetics of a single dose of Aficamten (CK‐274) on cardiac contractility in a A31PMYBPC3 hypertrophic cardiomyopathy cat model
4个月前
已完结
RAS-targeted therapies: is the undruggable drugged?
5个月前
已完结
Abstract 6737: RAS inhibitors as payloads of ADCs to treat RAS-mutant tumors
5个月前
已关闭
Breakthrough in RAS targeting with pan-RAS(ON) inhibitors RMC-7977 and RMC-6236
5个月前
已完结
Combinatorial strategies to target RAS-driven cancers
6个月前
已完结
OA10.03 Phase I/II Study of Iza-Bren (BL-B01D1) as Monotherapy in Patients With Locally Advanced or Metastatic EGFR Mutated NSCLC
8个月前
已关闭
Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials
9个月前
已完结
The next generation of immunotherapies for lung cancers
10个月前
已完结
皖公网安备34019202002308
